Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

RISK FACTORS

ACE2 level as a marker of CVD

Nature Reviews Cardiology volume 17, page 759 (2020)Cite this article

Subjects

Higher levels of angiotensin-converting enzyme 2 (ACE2) in plasma are associated with a greater risk of major cardiovascular disease (CVD) events, according to a global, population-based study. ACE2 is a component of the counter-regulatory renin–angiotensin system, which has important roles in various CVDs. Moreover, ACE2 is the receptor used by SARS-CoV-2, the virus that causes COVID-19, to enter host cells. Therefore, understanding the function and prognostic role of ACE2 is of increasing importance.

A study including 10,753 participants from the PURE study, which enrolled participants from 14 countries across five continents, now shows that high ACE2 levels in plasma are associated with an increased risk of all-cause death as well as cardiovascular and non-cardiovascular deaths. Plasma ACE2 levels were also associated with a higher risk of incident heart failure, myocardial infarction, stroke and diabetes mellitus, independently of age, sex, ancestry and traditional risk factors for CVD. Except for incident heart failure, all associations remained significant after adjusting for B-type natriuretic peptide levels. Moreover, plasma ACE2 level was the highest-ranked predictor of death compared with established risk factors for CVD (smoking, diabetes, blood pressure, blood lipids and BMI) and was a better predictor of heart failure, stroke and myocardial infarction than several of the established risk factors. Men had higher plasma ACE2 levels than women; ACE2 levels varied by ancestry; and higher BMI, older age, diabetes, higher blood pressure, higher LDL-cholesterol level and smoking were associated with increased plasma ACE2 levels.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Related article

  • Paz Ocaranza, M. et al. Counter-regulatory renin–angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 17, 116–129 (2020)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cardiology http://www.nature.com/nrcardio/

    Irene Fernández-Ruiz

Authors
  1. Irene Fernández-Ruiz
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Irene Fernández-Ruiz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernández-Ruiz, I. ACE2 level as a marker of CVD. Nat Rev Cardiol 17, 759 (2020). https://doi.org/10.1038/s41569-020-00468-2

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41569-020-00468-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing